EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 308 participants.
Also called NCT03287609
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 308 participants
- Registry
-
NCT03287609
-
- Other papers using this trial's data
- Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Switzerland
- Registry status
- Completed
Technical summary
Registry record NCT03287609. Randomized; quadruple masking; primary purpose treatment. Start 2018-01-23 (actual); primary completion 2019-05-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)
- Acronym
- EVOPACS
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- Evolocumab 140 mg/mL
- Intervention (Drug)
- Placebo
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Collaborator
- Amgen
- Collaborator
- University of Bern
Record details
- Record id
cardio:ct-nct03287609- Content hash
bbb4f0d7c2829401249a078a570e3da3d9dbd8bc907281e567f3b3ec53dac656